BioCryst Pharmaceuticals BCRX Deferred taxes
Deferred taxes at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxExpenseBenefit.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's deferred taxes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's deferred taxes?
- BioCryst Pharmaceuticals (BCRX) reported deferred taxes of -$303K in Q4 2025.
- How has BioCryst Pharmaceuticals's deferred taxes changed year-over-year?
- BioCryst Pharmaceuticals's deferred taxes decreased by 242.4% year-over-year, from -$88.5K to -$303K.
- What is the long-term trend for BioCryst Pharmaceuticals's deferred taxes?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's deferred taxes has grown at a 66.2% compound annual growth rate (CAGR), from -$159K to -$1.21M.
- What does deferred taxes mean?
- Captures the net change in deferred tax assets and liabilities during the reporting period, excluding current taxes. This metric is essential for evaluating how temporary accounting differences, such as depreciation or stock-based compensation, affect the company's future tax profile.